N/A N=32 Treatment

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

Cystic Fibrosis · Bronchiectasis

Bottom Line

View on ClinicalTrials.gov: NCT03534986 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2018

Primary outcome: Primary: TV — 0.93; 1.00; 1.07 L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: International Biophysics AffloVest (Device); Hill-Rom The Vest (Device); Respirtech inCourage (Device); Electromed SmartVest (Device)
Age: Adult · 18+ yrs
Sex: All
Sponsor: International Biophysics Corporation
Primary completion: Mar 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY TV	0.93; 1.00; 1.07	—
PRIMARY PEF	8.19; 8.28; 8.13	—
PRIMARY FVC	4.29; 4.25; 4.12	—
PRIMARY FEV1	3.51; 3.46; 3.30	—
PRIMARY FEF25-75%	3.71; 3.54; 3.19	—

Summary

The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of several products and comparing to baseline values.

Eligibility Criteria

Inclusion Criteria

Healthy subject, ages 18 - 50

Exclusion Criteria

Non-ambulatory, diagnosed neuromuscular disorder, currently using any type of oscillation vest therapy, diagnosed co-morbid condition (i.e. lung cancer, other lung disorder or disease), currently enrolled in a medical research study, non-English speaking

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03534986). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.